FLT3 and acute myeloid leukemia: Notably, this trend was observed retrospectively in a single-tertiary-center study evaluating differences in clinical outcomes in patients with newly diagnosed FLT3-ITD-mutated AML from 2000 to 2014, whereby a higher proportion of patients achieved CR in successive years and the corresponding median OS and median time to relapse increased significantly and incrementally over time with the introduction of alloHSCT and FLT3 inhibitors for the treatment of patients with FLT3-ITD mutations [55].